Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone

Journal of Infection

Volumn 74, Issue 3, 2017, Pages 302-309

  Sahr, F ^a,b   Ansumana, R ^c,d   Massaquoi, T A ^a   Idriss, B R ^a,b   Sesay, F R ^a   Lamin, J M ^c,d   Baker, S ^e   Nicol, S ^f   Conton, B ^g   Johnson, W ^b,e   Abiri, O T ^b,e   Kargbo, O ^e   Kamara, P ^e   Goba, A ^h   Russell, J B W ^b,e   Gevao, S M ^b,e  

^a 34 Military Hospital   (Sierra Leone)

^b Infectious Diseases Unit   (Sierra Leone)

^c Mercy Hospital Research Laboratory   (Sierra Leone)

^d NJALA UNIVERSITY   (Sierra Leone)

^e MINISTRY OF HEALTH AND SANITATION   (Sierra Leone)

^f Davidson Nicol Memorial Hospital   (Sierra Leone)

^g Physio Fitness and Rehabilitation Centre   (Sierra Leone)

^h Kenema Government Hospital   (Sierra Leone)

Author keywords

Convalescent whole blood; EVD; Sierra Leone; Treatment

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CONVALESCENT WHOLE BLOOD; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FATALITY; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY RATE; PRESCHOOL CHILD; SCHOOL CHILD; SIERRA LEONE; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT; CONVALESCENCE; DRUG EFFECTS; EPIDEMIC; HEMORRHAGIC FEVER, EBOLA; HOSPITALIZATION; MORTALITY; ODDS RATIO; PASSIVE IMMUNIZATION;

ANTISERUM;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CHILD; CONVALESCENCE; DISEASE OUTBREAKS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HOSPITALIZATION; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; MALE; MIDDLE AGED; ODDS RATIO; SIERRA LEONE; VIRAL LOAD; YOUNG ADULT;

EID: 85007447719     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.11.009     Document Type: Article

References (22)

1. [1] Edmond, R.T., Evans, B., Bowen, E.T., Lloyd, G., A case of Ebola virus infection. Br Med J 2:6086 (1977), 541–544.
2. [2] Courtois, D., Ebola virus three years later. Med Trop (Mars) 39:6 (1979), 675–684.
3. [3] Mupapa, K., Massamba, M., Kibadi, K., Kuvula, K., Bwaka, A., Kipasa, M., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179:Suppl. 1 (1999), S18–S23.
4. [4] Sadek, R.F., Khan, A.S., Stevens, G., Peters, C.J., Ksiazek, T.G., Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 179:Suppl. 1 (1999), S24–S27, 10.1086/514311.
5. [5] Jahrling, P.B., Geisbert, J.B., Swearengen, J.R., Larsen, T., Geisbert, T.W., Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 196:2 (2007), S400–S403.
6. [6] Parry, R.P., Tettmar, K.I., Hoschler, K., Brailsford, S.R., Samuel, D., Ashford, M., et al. Strategies for screening blood donors to source convalesc ent H1N1v plasma for intervention therapy. Vox Sang 103:2 (2012), 107–112.
7. [7] HUBER, H.G., [Status of treatment with poliomyelitis convalescent serum]. Kinderarztl Prax 21:7 (1953), 311–314.
8. [8] Gundersen, T., Convalescent blood for treatment of herpes zoster pphthalmicus: second report. Trans Am Ophthalmol Soc 38 (1940), 124–137.
9. [9] Wong, V.W.S., Dai, D., Wu, A.K.L., Sung, J.J.Y., Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 9:3 (2003), 199–201.
10. [10] Yeh, K.M., Chiueh, T.S., Siu, L.K., Lin, J.C., Chan, P.K.S., Peng, M.Y., et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 56:5 (2005), 919–922, 10.1093/jac/dki346.
11. [11] Mair-Jenkins, J., Saavedra-Campos, M., Baillie, K., Cleary, P., Khaw, F.-M., Lim, W.S., et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a systematic review and exploratory meta-analysis. J Infect Dis 211 (2015), 80–90, 10.1093/infdis/jiu396.
12. [12] Hung, I.F., To, K.K., Lee, C.K., Lee, K.L., Chan, K., Yan, W.W., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52:4 (2011), 447–456, 10.1093/cid/ciq106.
13. [13] van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M.G., Gallian, P., Baize, S., et al. Evaluation of convalescent plasma for Ebola Virus Disease in Guinea. N Engl J Med 374:1 (2016), 33–42, 10.1056/NEJMoa1511812.
14. [14] van Griensven, J., De Weiggheleire, A., Delamou, A., Smith, P.G., Edwards, T., Vandekerckhove, P., et al. The use of Ebola convalescent plasma to treat Ebola Virus Disease in resource-constrained settings: a perspective from the field. Clin Infect Dis 62:1 (2016), 69–74, 10.1093/cid/civ680.
15. [15] Burnouf, T., Seghatchian, J., Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci 51:2 (2014), 120–125, 10.1016/j.transci.2014.10.003.
16. [16] Thompson, J.B., Mejabi, P.F., Mejabi, O.O., Tejan-Sie, S.A., Convalescent serum therapy as rapid advance treatment for Ebola in West Africa. Int J African Dev 2:2 (2015), 58–70, 10.1007/s13398-014-0173-7.2.
17. [17] Campbell, D.E., Georgiou, G.M., Kemp, A.S., Pooled human immunoglobulin inhibits IL-4 but not IFN-gamma or TNF-alpha secretion following in vitro stimulation of mononuclear cells with Staphylococcal superantigen. Cytokine 11:5 (1999), 359–365, 10.1006/cyto.1998.0435.
18. [18] Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J.B., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:7520 (2014), 47–53, 10.1038/nature13777.
19. [19] Marano, G., Vaglio, S., Pupella, S., Facco, G., Catalano, L., Liumbruno, G.M., et al. Convalescent plasma: new evidence for an old therapeutic tool?. Blood Transfus 14 (2016), 152–157, 10.2450/2015.0131-15.
20. [20] Organization World Health, Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Interim Guid Natl Heal Authorities Blood Transfus Serv, 2014, 1–19 WHO/HIS/SDS/2014.8 http://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/.
21. [21] Ansumana, R., Jacobsen, K.H., Sahr, F., Idris, M., Bangura, H., Boie-Jalloh, M., et al. Ebola in Freetown area, Sierra Leone–a case study of 581 patients. N Engl J Med 372:6 (2015), 587–588, 10.1056/NEJMc1413685.
22. [22] Fitzpatrick, G., Vogt, F., Moi Gbabai, O.B., Decroo, T., Keane, M., De Clerck, H., et al. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Médecins Sans Frontières Ebola Case Management Centre, Kailahun, Sierra Leone, June–October 2014. J Infect Dis 212:10 (2015), 1752–1758, 10.1093/infdis/jiv304.